Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Biofrontera Inc. Warrants (BFRIW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/14/2025: BFRIW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -27.08% | Avg. Invested days 34 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/14/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.3 | 52 Weeks Range 0.01 - 0.23 | Updated Date 06/3/2025 |
52 Weeks Range 0.01 - 0.23 | Updated Date 06/3/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.3 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -30.33% | Operating Margin (TTM) -52.95% |
Management Effectiveness
Return on Assets (TTM) -49.47% | Return on Equity (TTM) -384.98% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 7102407 |
Shares Outstanding - | Shares Floating 7102407 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Biofrontera Inc. Warrants
Company Overview
History and Background
Biofrontera Inc. is a biopharmaceutical company specializing in the development and commercialization of dermatological products. Its warrants represent the right to purchase shares of Biofrontera Inc. at a specified price and expiration date.
Core Business Areas
- Prescription Drugs: Development and commercialization of prescription drugs for the treatment of dermatological conditions such as actinic keratosis.
- Cosmetics: Development and commercialization of cosmetic products.
Leadership and Structure
Biofrontera Inc. is led by a management team with expertise in dermatology and pharmaceuticals. Its organizational structure includes departments for research and development, sales and marketing, and regulatory affairs.
Top Products and Market Share
Key Offerings
- Ameluz: A topical prescription drug used in combination with red light photodynamic therapy (PDT) for the treatment of actinic keratosis. Competitors include Picato (ingenol mebutate) and Levulan Kerastick (aminolevulinic acid). Market share data is not explicitly available.
Market Dynamics
Industry Overview
The dermatology market is driven by aging populations, increasing awareness of skin conditions, and advancements in treatment options.
Positioning
Biofrontera Inc. focuses on PDT for actinic keratosis, offering a specific treatment modality. It competes with other topical treatments and procedures.
Total Addressable Market (TAM)
The TAM for actinic keratosis treatment is significant and growing, estimated to be in the billions of dollars globally. Biofrontera's positioning is focused, targeting a specific segment of this market.
Upturn SWOT Analysis
Strengths
- Specialized expertise in photodynamic therapy
- Approved product (Ameluz)
- Strong patent protection for key products
Weaknesses
- Limited product portfolio
- High reliance on a single product
- Relatively small market share compared to larger pharmaceutical companies
Opportunities
- Expansion into new markets
- Development of new dermatological products
- Partnerships with other pharmaceutical companies
Threats
- Competition from established pharmaceutical companies
- Patent expirations
- Changes in regulatory requirements
Competitors and Market Share
Key Competitors
- LEO (LEO.CO)
- PTON
- ALNY
Competitive Landscape
Biofrontera Inc. competes with larger pharmaceutical companies and other dermatology-focused businesses. Its competitive advantage lies in its specialized focus on PDT and its proprietary technology.
Growth Trajectory and Initiatives
Historical Growth: Biofrontera Inc.'s historical growth has been driven by the adoption of Ameluz. Growth trends vary and are dependent on market conditions and execution of the growth strategy.
Future Projections: Future growth projections are dependent on market conditions, analyst estimates, and the company's ability to execute its strategy.
Recent Initiatives: Recent initiatives include new clinical trials, market expansion efforts, and product development programs.
Summary
Biofrontera Inc. is a biopharmaceutical company focusing on dermatology, particularly actinic keratosis treatments. It has a specialized technology (PDT) and an approved product (Ameluz). However, it has a limited product portfolio, which exposes it to competition and regulatory challenges. Future growth will depend on expanding its market reach, developing new products, and forming strategic partnerships.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company reports and filings
- Industry analysis reports
- Market research data
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual circumstances and thorough research.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Biofrontera Inc. Warrants
Exchange NASDAQ | Headquaters Woburn, MA, United States | ||
IPO Launch date 2021-10-29 | CEO, President & Chairman Dr. Hermann Luebbert Ph.D. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 92 | Website https://www.biofrontera-us.com |
Full time employees 92 | Website https://www.biofrontera-us.com | ||
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a common skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.